ArriVent BioPharma (NASDAQ:AVBP) Sees Unusually-High Trading Volume – Should You Buy?

Shares of ArriVent BioPharma, Inc. (NASDAQ:AVBP) saw strong trading volume on Tuesday . 640,535 shares changed hands during mid-day trading, an increase of 25% from the previous session’s volume of 513,547 shares.The stock last traded at $26.3360 and had previously closed at $24.81.

Analysts Set New Price Targets

Several equities research analysts have weighed in on the company. BTIG Research began coverage on ArriVent BioPharma in a report on Wednesday, December 10th. They issued a “buy” rating and a $45.00 price objective for the company. Citigroup upped their target price on ArriVent BioPharma from $31.00 to $33.00 and gave the company a “buy” rating in a report on Friday. Truist Financial began coverage on shares of ArriVent BioPharma in a report on Tuesday, November 25th. They issued a “buy” rating and a $43.00 price target on the stock. Zacks Research raised shares of ArriVent BioPharma from a “strong sell” rating to a “hold” rating in a research report on Friday, December 5th. Finally, Oppenheimer reaffirmed an “outperform” rating and issued a $50.00 target price (up from $44.00) on shares of ArriVent BioPharma in a research report on Friday. One research analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $41.11.

ArriVent BioPharma Stock Up 7.1%

The company has a market capitalization of $1.17 billion, a P/E ratio of -5.97 and a beta of 0.98. The company has a 50-day moving average of $22.28 and a two-hundred day moving average of $20.98.

ArriVent BioPharma (NASDAQ:AVBP) last posted its quarterly earnings data on Thursday, March 5th. The company reported ($0.78) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.87) by $0.09. As a group, equities analysts expect that ArriVent BioPharma, Inc. will post -2.74 EPS for the current fiscal year.

Institutional Investors Weigh In On ArriVent BioPharma

Hedge funds have recently bought and sold shares of the business. Dynamic Technology Lab Private Ltd purchased a new stake in ArriVent BioPharma in the first quarter worth about $266,000. Woodline Partners LP boosted its position in shares of ArriVent BioPharma by 0.4% in the 1st quarter. Woodline Partners LP now owns 146,373 shares of the company’s stock worth $2,706,000 after purchasing an additional 576 shares in the last quarter. Jane Street Group LLC purchased a new stake in shares of ArriVent BioPharma in the 1st quarter worth approximately $189,000. SG Americas Securities LLC raised its stake in ArriVent BioPharma by 21.1% during the second quarter. SG Americas Securities LLC now owns 27,473 shares of the company’s stock valued at $598,000 after buying an additional 4,793 shares during the last quarter. Finally, Legal & General Group Plc boosted its holdings in ArriVent BioPharma by 8.8% in the second quarter. Legal & General Group Plc now owns 14,790 shares of the company’s stock worth $322,000 after acquiring an additional 1,197 shares in the last quarter. Institutional investors own 9.48% of the company’s stock.

ArriVent BioPharma Company Profile

ArriVent BioPharma, Inc operates as a clinical-stage biopharmaceutical company that engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers in the United States. It also engages in the development and commercialization of targeted cancer therapies for non-small cell lung cancer (NSCLC) and other solid tumors. In addition, the company develops Furmonertinib, a third-generation tyrosine kinase inhibitor that is in multiple clinical trials across a range of epidermal growth factor receptor mutations (EFGRm) in non-small cell lung cancer (NSCLC), including a phase 3 clinical trial for treatment of patients with metastatic EFGRm NSCLC; phase 1b clinical trial for treatment of patients with NSCLC with other EGFR mutations and NSCLC with HER2 Exon 20 insertion mutations; and ARR-002.